Exploring the innovation behind acquired companies
Acquisitions
Oct 5, 2026
•
15 min read
How four professors teamed up with a serial entrepreneur to teach an old drug new tricks
Sep 21, 2026
13 min read
Nuclear fusion between two radiopharmaceutical powerhouses
Aug 31, 2026
9 min read
Laying traps for antibody rebels
Aug 18, 2026
11 min read
Rare disease maven bets on a next generation bone-forming medicine
Aug 10, 2026
How David Goldstein's precision neuroscience thesis hit escape velocity
Aug 8, 2026
Exploring the Pax Pharmaceutica that never arrived
Jul 27, 2026
10 min read
How Paul Wagner's pivot from microbiome medicines to CD122 for celiac and vitiligo paid off
Jul 16, 2026
SSRI/SNRI powerhouse bets on neuroplasticity for depression
Jul 7, 2026
How R. Scott Struthers and his crew from Neurocrine went out on their own and struck gold in rare metabolic disease
Jul 6, 2026
8 min read
Another preclinical ADC payload company exits north of a billion dollars
Jul 2, 2026
Regenerative medicine titans join forces to grow a thymus
Jul 1, 2026
12 min read
Neutralizing the viral ghosts that haunt kidney transplant patients
Jun 29, 2026
Unleashing apoptotic p53 on myelofibrosis
7 min read
M&A alchemy with a COPD sweetener
Jun 22, 2026
Paragon's long-acting atopic dermatitis & asthma pipeline pays off
Jun 18, 2026
Qing Dong and Gene Hung pull off a third act with oral immunology me-betters
Jun 16, 2026
Ted Price's hunt for non-opioid painkillers pays off
Jun 9, 2026
17 min read
Bolting on a three-headed hydra of targeted lung cancer drugs
Jun 8, 2026
A bold bet on novel discoveries in a rare bleeding disorder pays off
An ADC degrader play with a Nobel and rock & roll twist
Jun 1, 2026
A contrarian bet on skeletal myosin pays off
May 26, 2026
Re-entering the vaccine market with multiple sclerosis (MS) upside
May 20, 2026
A founder-led startup aiming to solve gene therapy's "last mile" problem
May 6, 2026
A long-acting diabetic eye disease play
May 4, 2026
Scooping a reverse merger for a TCE pipeline
